name: 'cart-design-optimizer-agent'
description: 'AI-guided CAR-T cell design for solid tumors using antigen prioritization, safety-by-design architectures, and exhaustion-resistant engineering.'
measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.
allowed-tools:
- read_file
- run_shell_command
CAR-T Design Optimizer Agent
The CAR-T Design Optimizer Agent provides end-to-end AI-guided design of chimeric antigen receptor T-cells. It integrates antigen prioritization, safety-constrained CAR architectures, exhaustion resistance engineering, and computational modeling of CAR-T kinetics for optimized therapeutic design.
When to Use This Skill
- When designing CAR-T therapies for solid tumors with limited target antigens.
- To optimize CAR construct sequences for reduced exhaustion and self-activation.
- For selecting safety-by-design architectures (logic-gated, modular, armored).
- When predicting CAR-T expansion, persistence, and efficacy.
- To engineer exhaustion-resistant CAR-T cells via gene editing strategies.
Core Capabilities
Antigen Prioritization: AI-driven ranking of target antigens based on tumor specificity, expression levels, and safety profiles.
CARMSeD Prediction: Predictive model forecasting CAR constructs prone to tonic signaling, self-activation, and dysfunction.
Safety Architecture Design: Logic-gated (synNotch), ON/OFF switches, armored designs for solid tumor safety.
Exhaustion Resistance: CRISPR target selection (TOX, NR4A, PD-1 knockouts) and PD-1 locus integration strategies.
Pharmacokinetic Modeling: Multi-population models predicting CAR-T expansion, distribution, and persistence.
LLM-Assisted Design: Constrained large language model reasoning for evidence synthesis and design justification.
CAR Architecture Options
| Architecture |
Mechanism |
Best For |
| Standard 2nd Gen |
CD28 or 4-1BB costimulation |
Hematological malignancies |
| Logic-Gated (AND) |
Requires 2 antigens for activation |
Solid tumors, safety |
| synNotch Priming |
TME signal triggers CAR expression |
Local activation |
| Armored CAR |
Cytokine secretion (IL-15, IL-21) |
Hostile TME |
| Universal/SUPRA |
Adaptable targeting via adaptor |
Multi-antigen, flexibility |
| PD-1 Knock-in |
CAR in PD-1 locus |
Exhaustion resistance |
Workflow
Antigen Selection: Analyze tumor expression data to prioritize targets.
Safety Assessment: Evaluate off-tumor expression in normal tissues.
CAR Design: Generate construct sequences with selected domains.
CARMSeD Screening: Predict self-activation and exhaustion propensity.
Architecture Selection: Match patient/tumor to optimal CAR design.
Gene Editing Design: Select CRISPR targets for enhanced function.
Output: Optimized CAR sequence, predicted performance, manufacturing specs.
Example Usage
User: "Design an optimized CAR-T construct targeting HER2 for breast cancer with minimized exhaustion."
Agent Action:
python3 Skills/Immunology_Vaccines/CART_Design_Optimizer_Agent/cart_designer.py \
--target HER2 \
--tumor_type breast_cancer \
--expression_data tumor_rnaseq.tsv \
--normal_tissues gtex_expression.tsv \
--architecture synnotch_armored \
--exhaustion_engineering tox_knockout \
--model carmsed_v2 \
--output cart_design_report/
CARMSeD Model Details
Prediction Targets:
- Tonic signaling propensity
- Self-activation risk
- Exhaustion trajectory
- Proliferative capacity
Input Features:
- scFv binding affinity
- Hinge/spacer length
- Costimulatory domain
- Transmembrane sequence
- Expression system
Validated Performance:
- AUC > 0.85 for dysfunction prediction
- In vitro to in vivo correlation
Anti-Exhaustion Engineering Strategies
| Target |
Method |
Effect |
| TOX |
CRISPR KO |
Prevents exhaustion program |
| NR4A1-3 |
Triple KO |
Blocks exhaustion TFs |
| PD-1 locus |
CAR integration |
TME-responsive expression |
| c-Jun |
Overexpression |
Overcomes AP-1 imbalance |
| DNMT3A |
KO |
Epigenetic reprogramming |
Computational Pharmacokinetics
Lotka-Volterra Model:
dC/dt = r*C*(1 - C/K) - k*C*T # CAR-T expansion
dT/dt = -α*C*T # Tumor killing
Multi-Population Extensions:
- Memory vs. effector subsets
- Exhaustion state transitions
- Cytokine-mediated effects
- Checkpoint interactions
Prerequisites
- Python 3.10+
- PyTorch for ML models
- CRISPRscan for guide design
- Protein structure tools (optional)
Related Skills
- TCell_Exhaustion_Analysis_Agent - For exhaustion profiling
- Neoantigen_Vaccine_Agent - For antigen identification
- CRISPR_Design_Agent - For gene editing optimization
Clinical Considerations
- Cytokine Release Syndrome: Risk assessment and mitigation designs
- ICANS Neurotoxicity: CNS penetration modeling
- Manufacturing: Transduction efficiency predictions
- Persistence: Memory phenotype engineering
Author
AI Group - Biomedical AI Platform
1---2name: cart-design-optimizer-agent3description: <!--4---5<!--6# COPYRIGHT NOTICE7# This file is part of the "Universal Biomedical Skills" project.8# Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>9# All Rights Reserved.10#11# This code is proprietary and confidential.12# Unauthorized copying of this file, via any medium is strictly prohibited.13#14# Provenance: Authenticated by MD BABU MIA1516-->1718---19name: 'cart-design-optimizer-agent'20description: 'AI-guided CAR-T cell design for solid tumors using antigen prioritization, safety-by-design architectures, and exhaustion-resistant engineering.'21measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.22allowed-tools:23 - read_file24 - run_shell_command25---262728# CAR-T Design Optimizer Agent2930The **CAR-T Design Optimizer Agent** provides end-to-end AI-guided design of chimeric antigen receptor T-cells. It integrates antigen prioritization, safety-constrained CAR architectures, exhaustion resistance engineering, and computational modeling of CAR-T kinetics for optimized therapeutic design.3132## When to Use This Skill3334* When designing CAR-T therapies for solid tumors with limited target antigens.35* To optimize CAR construct sequences for reduced exhaustion and self-activation.36* For selecting safety-by-design architectures (logic-gated, modular, armored).37* When predicting CAR-T expansion, persistence, and efficacy.38* To engineer exhaustion-resistant CAR-T cells via gene editing strategies.3940## Core Capabilities41421. **Antigen Prioritization**: AI-driven ranking of target antigens based on tumor specificity, expression levels, and safety profiles.43442. **CARMSeD Prediction**: Predictive model forecasting CAR constructs prone to tonic signaling, self-activation, and dysfunction.45463. **Safety Architecture Design**: Logic-gated (synNotch), ON/OFF switches, armored designs for solid tumor safety.47484. **Exhaustion Resistance**: CRISPR target selection (TOX, NR4A, PD-1 knockouts) and PD-1 locus integration strategies.49505. **Pharmacokinetic Modeling**: Multi-population models predicting CAR-T expansion, distribution, and persistence.51526. **LLM-Assisted Design**: Constrained large language model reasoning for evidence synthesis and design justification.5354## CAR Architecture Options5556| Architecture | Mechanism | Best For |57|--------------|-----------|----------|58| Standard 2nd Gen | CD28 or 4-1BB costimulation | Hematological malignancies |59| Logic-Gated (AND) | Requires 2 antigens for activation | Solid tumors, safety |60| synNotch Priming | TME signal triggers CAR expression | Local activation |61| Armored CAR | Cytokine secretion (IL-15, IL-21) | Hostile TME |62| Universal/SUPRA | Adaptable targeting via adaptor | Multi-antigen, flexibility |63| PD-1 Knock-in | CAR in PD-1 locus | Exhaustion resistance |6465## Workflow66671. **Antigen Selection**: Analyze tumor expression data to prioritize targets.68692. **Safety Assessment**: Evaluate off-tumor expression in normal tissues.70713. **CAR Design**: Generate construct sequences with selected domains.72734. **CARMSeD Screening**: Predict self-activation and exhaustion propensity.74755. **Architecture Selection**: Match patient/tumor to optimal CAR design.76776. **Gene Editing Design**: Select CRISPR targets for enhanced function.78797. **Output**: Optimized CAR sequence, predicted performance, manufacturing specs.8081## Example Usage8283**User**: "Design an optimized CAR-T construct targeting HER2 for breast cancer with minimized exhaustion."8485**Agent Action**:86```bash87python3 Skills/Immunology_Vaccines/CART_Design_Optimizer_Agent/cart_designer.py \88 --target HER2 \89 --tumor_type breast_cancer \90 --expression_data tumor_rnaseq.tsv \91 --normal_tissues gtex_expression.tsv \92 --architecture synnotch_armored \93 --exhaustion_engineering tox_knockout \94 --model carmsed_v2 \95 --output cart_design_report/96```9798## CARMSeD Model Details99100**Prediction Targets**:101- Tonic signaling propensity102- Self-activation risk103- Exhaustion trajectory104- Proliferative capacity105106**Input Features**:107- scFv binding affinity108- Hinge/spacer length109- Costimulatory domain110- Transmembrane sequence111- Expression system112113**Validated Performance**:114- AUC > 0.85 for dysfunction prediction115- In vitro to in vivo correlation116117## Anti-Exhaustion Engineering Strategies118119| Target | Method | Effect |120|--------|--------|--------|121| TOX | CRISPR KO | Prevents exhaustion program |122| NR4A1-3 | Triple KO | Blocks exhaustion TFs |123| PD-1 locus | CAR integration | TME-responsive expression |124| c-Jun | Overexpression | Overcomes AP-1 imbalance |125| DNMT3A | KO | Epigenetic reprogramming |126127## Computational Pharmacokinetics128129**Lotka-Volterra Model**:130```131dC/dt = r*C*(1 - C/K) - k*C*T # CAR-T expansion132dT/dt = -α*C*T # Tumor killing133```134135**Multi-Population Extensions**:136- Memory vs. effector subsets137- Exhaustion state transitions138- Cytokine-mediated effects139- Checkpoint interactions140141## Prerequisites142143* Python 3.10+144* PyTorch for ML models145* CRISPRscan for guide design146* Protein structure tools (optional)147148## Related Skills149150* TCell_Exhaustion_Analysis_Agent - For exhaustion profiling151* Neoantigen_Vaccine_Agent - For antigen identification152* CRISPR_Design_Agent - For gene editing optimization153154## Clinical Considerations1551561. **Cytokine Release Syndrome**: Risk assessment and mitigation designs1572. **ICANS Neurotoxicity**: CNS penetration modeling1583. **Manufacturing**: Transduction efficiency predictions1594. **Persistence**: Memory phenotype engineering160161## Author162163AI Group - Biomedical AI Platform164165166<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->